Reported 2 months ago
The FDA has rejected the use of MDMA as a treatment for PTSD, marking a significant setback for advocates seeking to use psychedelics for mental health. The agency requested further studies to address safety and efficacy concerns after a review uncovered significant limitations in the drug's application. Lykos Therapeutics, the manufacturer, expressed disappointment but plans to appeal. The decision follows a trend of increasing scrutiny on the use of MDMA and supports the continuation of psychedelic research for therapeutic purposes.
Source: YAHOO